Endocrine Abstracts

Introduction: Approximately 20% of patients with prolactinomas do not respond satisfactory (resistant) even to high dose dopamine agonist treatment. Worth noticing that there are no clear prognostic signs of treatment’s resistance as well as its etiology is a subject of discussion. Aim: The aim of our study was to assessabsorption and metabolism of cabergoline in patients with dopamine agonist-resistant prolactinomas.Materials...

Introduction: Prolactinomas are the most common type of pituitary adenomas(40% of them), representing a significant cause of infertility and hypogonadism. About 20% of patients with prolactinomas don’t respond satisfactory(i.e. resistant) even to high dose dopamine agonist(DA) treatment(>3.5–4.5 mg/week). Worth noticing that there are no clear signs to anticipate this resistance but to stepwise increase the dose of DA. In addition, the etiology of resistance &#15...